CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Antifungal therapy authorization (unspecified agent)

Defines clinical criteria for prior authorization of an antifungal agent for various invasive fungal infections and prophylaxis in high-risk hematologic patients, including age limits, diagnostic requirements, and prior therapy failure requirements. Also specifies coverage duration.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyAntifungal therapy authorization (unspecified agent)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionAn authorization may be granted only when the listed age and diagnosis criteria (including documented prior antifungal failures where specified) are met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes; policy remains current with existing approval criteria.

5Distinct covered indications listed

>=2Minimum patient age (years)

0 monthsCoverage duration

Coverage Summary

Scope: Defines clinical criteria for prior authorization of an antifungal agent for various invasive fungal infections and prophylaxis in high-risk hematologic patients. Coverage is covered_with_criteria for the subject: Antifungal therapy authorization (unspecified agent).

Key stats: • Distinct covered indications listed: 5 • Minimum patient age (years): >=2 • Coverage duration: 0 months

Key policy facts

Distinct covered indications listed5

Minimum patient age (years)>=2

Coverage duration0 months

Coverage stancecovered_with_criteria

SubjectAntifungal therapy authorization (unspecified agent)

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyAntifungal therapy authorization (unspecified agent)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionAn authorization may be granted only when the listed age and diagnosis criteria (including documented prior antifungal failures where specified) are met.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Criteria for Approval

An authorization may be granted when all the following criteria are met:

ALL of the following

ANY of the following diagnoses (one required)
- ALL of the following
  - Patient is 2 years or older
  - Documented diagnosis of a serious infection caused by scedosporium and fusarium species
- ALL of the following
  - Patient is 2 years or older
  - Documented diagnosis of an invasive aspergillus infection
- ALL of the following
  - Patient is 2 years or older
  - Documented diagnosis of esophageal candidiasis or oropharyngeal candidiasis
  - Documented failure of or clinical inappropriateness to fluconazole and itraconazole
- ALL of the following
  - Patient is 2 years or older
  - Documented diagnosis of prevention of invasive aspergillus and candida fungal infections
  - Documentation of hematologic malignancy with neutropenia, hematopoietic stem cell transplant, or graft-versus-host disease
- ALL of the following
  - Patient is 2 years or older
  - Documented diagnosis of candidemia and disseminated candidiasis infections
  - Documented failure of or clinical inappropriateness to oral fluconazole

ref

title

nodes

criteria_group

note

label

threshold

text

children

Provider Actions / Authorization Requirements

Prior Authorization

Authorization required

An authorization may be granted only when the listed age and diagnosis criteria (including documented prior antifungal failures where specified) are met.

Documentation Required

Document prior therapy failure or inappropriateness

For esophageal/oropharyngeal candidiasis and candidemia/disseminated candidiasis, document failure of or clinical inappropriateness to fluconazole (and itraconazole for oropharyngeal/esophageal cases) in the medical record submitted for authorization.

Background

This policy covers clinical scenarios including authorization for treatment of invasive fungal infections such as those caused by Scedosporium and Fusarium species, and invasive Aspergillus infections when the listed criteria are met.

It also covers prophylaxis and treatment in high-risk hematologic patients — specifically for prevention of invasive Aspergillus and Candida infections in patients with hematologic malignancy with neutropenia, hematopoietic stem cell transplant, or graft-versus-host disease — and for esophageal/oropharyngeal candidiasis and candidemia/disseminated candidiasis when there is documented failure of or clinical inappropriateness to azole therapy (fluconazole; itraconazole as applicable).